Related Experiment Video

Updated: Sep 27, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.8K

Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Laetitia Lesire1, Florence Leroux1, Rebecca Deprez-Poulain1

  • 1INSERM U1177 Drugs and Molecules for Living Systems, Institut Pasteur de Lille, European Genomic Institute for Diabetes, University of Lille, F-59000 Lille, France.

Cells
|April 12, 2022
PubMed

Insights

Insulin-degrading enzyme (IDE) is implicated in metabolic and neuronal diseases. Emerging evidence suggests IDE

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Insulin-degrading enzyme (IDE) is a multifunctional protease with diverse substrates and cellular roles.
  • IDE is known for its involvement in metabolic and neuronal diseases.
  • Recent findings indicate IDE overexpression in various cancers, prompting investigation into its oncogenic role.

Purpose of the Study:

  • To review the evidence linking IDE to cancer development and resistance.
  • To elucidate the catalytic and non-catalytic functions of IDE in cancer cell proliferation.
  • To discuss the impact of IDE pharmacomodulation as a potential cancer therapeutic strategy.

Main Methods:

  • Literature review of studies on IDE and cancer.
  • Analysis of IDE's known functions, including insulin degradation, chaperone activity, and proteasome interaction.
  • Examination of preclinical data on IDE inhibition in cancer models.

Main Results:

  • IDE plays a role in cancer development and resistance through various mechanisms.
  • IDE's functions, both catalytic and non-catalytic, influence cancer cell proliferation.
  • Pharmacological modulation of IDE has shown promising results in preclinical cancer studies.

Conclusions:

  • IDE is emerging as a significant factor in cancer physiopathology.
  • IDE's multifaceted roles suggest it is a potential therapeutic target in oncology.
  • Targeting IDE offers a promising avenue for novel cancer treatment strategies.
Keywords:
cancerinsulin-degrading enzymetarget

More Related Videos

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

540
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.8K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
451
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
601
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
274
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.3K